Dominari Holdings Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dominari Holdings Inc.
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
New data show that a high dose of Intellia’s in vivo CRISPR-Cas9 based therapy is safe and effective for up to six months, which could unlock a new era in genetic disease treatment.
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
- Other Names / Subsidiaries
- Biospherics.net Incorporated
- Biospherix Ltd
- CBM BioPharma, Inc.
- Hoth Therapeutics, Inc.
- Spherix Consulting, Inc.
- Spherix Incorporated
- AIkido Pharma Inc.
- AIkido Labs, LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.